Trial Profile
CD38 expression levels and lymphocyte subsets, including CD38-positive Treg cells, before and after Daratumumab treatment in relapsed/refractory Multiple Myeloma Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association